| Understanding and using patient experiences as evidence in healthcare priority setting L Rand, M Dunn, I Slade, S Upadhyaya, M Sheehan Cost Effectiveness and Resource Allocation 17, 1-13, 2019 | 55 | 2019 |
| Patient and public involvement: Two sides of the same coin or different coins altogether? MS McCoy, J Warsh, L Rand, M Parker, M Sheehan Bioethics 33 (6), 708-715, 2019 | 42 | 2019 |
| National Standards for Public Involvement in Research: missing the forest for the trees MS McCoy, KR Jongsma, P Friesen, M Dunn, CP Neuhaus, L Rand, ... Journal of Medical Ethics 44 (12), 801-804, 2018 | 37 | 2018 |
| Power and limitations of daily prognostications of death in the medical ICU for outcomes in the following 6 months W Meadow, A Pohlman, D Reynolds, L Rand, C Correia, E Christoph, ... Critical Care Medicine 42 (11), 2387-2392, 2014 | 25 | 2014 |
| Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review: Systematic literature review examines the controversy over … LZ Rand, AS Kesselheim Health Affairs 40 (9), 1402-1410, 2021 | 24 | 2021 |
| Public involvement in the governance of population-level biomedical research: unresolved questions and future directions S Erikainen, P Friesen, L Rand, K Jongsma, M Dunn, A Sorbie, M McCoy, ... Journal of medical ethics 47 (7), 522-525, 2021 | 23 | 2021 |
| An international review of health technology assessment approaches to prescription drugs and their ethical principles LZ Rand, AS Kesselheim Journal of Law, Medicine & Ethics 48 (3), 583-594, 2020 | 17 | 2020 |
| International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects LZ Rand, AS Kesselheim Value in Health 24 (4), 473-476, 2021 | 12 | 2021 |
| Disentangling evidence and preference in patient-clinician concordance discussions LZG Rand, Z Berger AMA Journal of Ethics 21 (6), 505-512, 2019 | 9 | 2019 |
| Alternatives to the quality‐adjusted life year: How well do they address common criticisms? LZ Rand, GJ Melendez‐Torres, AS Kesselheim Health Services Research 58 (2), 433-444, 2023 | 6 | 2023 |
| We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment V Charlton, M DiStefano, P Mitchell, L Morrell, L Rand, G Badano, ... Health Economics, Policy and Law, 1-21, 2023 | 4 | 2023 |
| International reference pricing for prescription drugs: a landscape analysis LZ Rand, AS Kesselheim Journal of Managed Care & Specialty Pharmacy 27 (9), 1309-1313, 2021 | 4 | 2021 |
| Congress’ Misguided Plan to Ban QALYs LZ Rand, A Raymakers, BN Rome JAMA 329 (24), 2125-2126, 2023 | 3 | 2023 |
| What Should US Policymakers Learn From International Drug Pricing Transparency Strategies? S Nagar, LZ Rand, AS Kesselheim AMA Journal of Ethics 24 (11), 1083-1090, 2022 | 3 | 2022 |
| High-priced sickle cell gene therapies threaten to exacerbate us health disparities and establish new pricing precedents for molecular medicine FA Tessema, A Sarpatwari, LZ Rand, AS Kesselheim Journal of Law, Medicine & Ethics 50 (2), 380-384, 2022 | 3 | 2022 |
| Getting the price right: lessons for medicare price negotiation from peer countries LZ Rand, AS Kesselheim Pharmacoeconomics 40 (12), 1131-1142, 2022 | 2 | 2022 |
| Payments for research participation: don’t tax the guinea pig LZ Rand, AS Kesselheim Clinical Trials 19 (5), 579-583, 2022 | 2 | 2022 |
| Are Medicaid closed formularies unethical? L Rand, G Persad AMA Journal of Ethics 21 (8), 654-660, 2019 | 2 | 2019 |
| Prior Authorization as a Potential Support of Patient-Centered Care L Rand, Z Berger The Patient - Patient-Centered Outcomes Research 11 (4), 371-375, 2018 | 2 | 2018 |
| Legitimate priority-setting: refining accountability for reasonableness and its application within NICE L Rand University of Oxford, 2016 | 2 | 2016 |
